Longeveron® Announces Nature Medicine Publication Of Results Of Phase 2A Clinical Trial Evaluating Laromestrocel (Lomecel-B™) In Alzheimer’S Disease

Reuters
03-11
March 11 (Reuters) - Longeveron Inc ::
*LONGEVERON® ANNOUNCES NATURE MEDICINE PUBLICATION OF RESULTS OF PHASE 2A CLINICAL TRIAL EVALUATING LAROMESTROCEL (LOMECEL-B™) IN ALZHEIMER’S DISEASE
*LONGEVERON INC - LAROMESTROCEL FIRST CELLULAR THERAPY TO RECEIVE FDA RMAT DESIGNATION FOR ALZHEIMER'S
*LONGEVERON INC - TRIAL ACHIEVED PRIMARY SAFETY AND SECONDARY EFFICACY ENDPOINTS

((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 11-MAR-202512:30:00.797 GMT

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10